Abstract library

53 results for "glucose".
#2906 Change of Lactate Transporter (MCT4) Expression in Pancreatic Microadenomas and Stages of Pancreatic Neuroendocrine Tumors
Introduction: Metabolic changes are observed in early and late stages of Pancreatic Neuroendocrine Tumors (PanNET) in mouse models. In human PanNET, RNA-expression analysis showed changes in glucose metabolism in more aggressive PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Konstantin Bräutigam
#2737 Identification of a Novel MAFA Missense Mutation Causing Familial Insulinomatosis
Introduction: Insulinomatosis is a rare pancreatic disease characterized by an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PD. Dr. Christian Fottner
#2761 Diagnosis and Management of Insulinomas. The Use of Current Practices in Pakistan
Introduction: Insulinomas are rare functional and benign neuroendocrine tumors of Pancreas.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours
Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MBBS Kishen Patel
Authors: Patel K, Nahar A, Elhassan Y, Shah T, ...
#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes
Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
Authors: Kong G, Callahan J, Prall O, Michael M, ...
#2925 A Single Centre Experience of Open Surgery for Pancreatic Insulinomas on 88 Patients
Introduction: Insulinomas are functioning pancreatic neuroendocrine neoplasms (NENs), typically small and with a benign clinical course in more than 90% of cases.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2935 Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Ameya Puranik
#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Antwi Antwi
#19 Antitumor activity of Pasireotide (SOM230) alone and in combination with Everolimus (RAD001) in DU-145 human prostate cancer model
Introduction: Pasireotide (SOM230) is a novel multi-receptor ligand somatostatin analogue with high affinity for somatostatin receptor subtypes sst1,2,3 and sst5. Like octreotide, which binds primarily to sst2, it inhibits hypersecretion of hormones from patients with functional pituitary tumors and gastroenteropancreatic neuroendocrine (GEP/NET) tumors. In addition, tumor shrinkage has been observed with both compounds in patients with acromegaly, Cushing’s disease and GEP/NETs, but its tumor-reducing mechanism of action has so far not been revealed. In patients with breast and liver cancer, octreotide had little or no antitumor activity.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Herbert A. Schmid
Authors: Schmid H A, Chiara L, Nuciforo P, ...
#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma
Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Sara De Dosso